Cinoxacin: Quinolone Antibiotic Benchmarks for Gram-Negative Bacterial Research

Executive Summary: Cinoxacin (CAS 28657-80-9) is a synthetic organic acid antibiotic of the quinolone class, exhibiting potent inhibition of bacterial DNA replication at MICs of 2–8 μg/ml for most Gram-negative bacteria (APExBIO). Its pharmacokinetics—70% serum protein binding, renal elimination with 60% unchanged excreted, and a 1-hour half-life—are well defined (APExBIO, FDA). Cinoxacin is ineffective against Pseudomonas aeruginosa and Gram-positive species at MIC <64 μg/ml (APExBIO). Laboratory assays employ 1–256 μg/ml concentrations with a 30 μg disk standard for diffusion susceptibility testing. The BA1045 kit from APExBIO offers reproducible, research-grade material for antibiotic resistance and UTI model studies (see workflows).

Biological Rationale

Cinoxacin is designed for the study of Gram-negative aerobic bacteria, particularly pathogens involved in urinary tract infections (UTIs) such as Escherichia coli, Proteus mirabilis, and Klebsiella species (APExBIO). Its selectivity for bacterial DNA synthesis makes it a valuable tool for dissecting the DNA replication pathway, understanding quinolone mechanism of action, and investigating the evolution of antibiotic resistance in Gram-negative bacteria. Cinoxacin's defined pharmacokinetic and pharmacodynamic parameters enable researchers to model clinically-relevant infection scenarios and address dosing challenges in translational microbiology (precision antimicrobial solutions).

Mechanism of Action of Cinoxacin

Cinoxacin is a quinolone antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential enzymes for DNA replication, transcription, and repair (advanced research applications). The inhibition impedes supercoiling and strand separation of bacterial DNA, resulting in rapid bactericidal activity. Cinoxacin’s mechanism closely mirrors that of nalidixic acid, with cross-resistance frequently observed between the two agents. At a standard inoculum of 5×10⁶ cfu/ml, Cinoxacin reduces viable colony counts by at least 3 log₁₀ in susceptible Gram-negative strains. Resistance typically arises via target enzyme mutation or efflux pump upregulation, making it a strategic probe for resistance pathway studies.

Evidence & Benchmarks

• Cinoxacin exhibits MIC values of 2–8 μg/ml for most E. coli, Proteus mirabilis, and Klebsiella isolates; MIC >64 μg/ml required for Pseudomonas and Gram-positive species (APExBIO).
• Standard disk diffusion assays use a 30 μg Cinoxacin disk; interpretive breakpoints mirror those for nalidixic acid (FDA, ATCC guidelines).
• Serum protein binding is approximately 70%, impacting free drug levels in pharmacodynamic models (APExBIO).
• Renal elimination is dominant (60% excreted unchanged), and half-life is ~1 hour in healthy adults (FDA label, APExBIO).
• Effective urinary concentrations are achieved within 2 hours of oral dosing, peaking at 4–6 hours, and remain above MIC for 12 hours in most UTI models (APExBIO).
• Adverse effects include mild gastrointestinal and neurological symptoms at therapeutic doses (FDA label).

Applications, Limits & Misconceptions

Cinoxacin is primarily used in laboratory studies of Gram-negative urinary pathogens. Its robust activity enables cell viability, proliferation, and cytotoxicity assays in model organisms and clinical isolates (mechanistic insight). Applications include:

• Antibiotic resistance studies: Dissecting mechanisms and cross-resistance with nalidixic/oxolinic acid.
• UTI and prostatitis models: Benchmarking against contemporary fluoroquinolones.
• MIC and disk diffusion protocols: Standardized susceptibility testing for Gram-negative bacteria.
• Comparative pharmacokinetics and drug transport studies.
• Screening of efflux and DNA gyrase mutants.

Common Pitfalls or Misconceptions

• Not effective against Pseudomonas aeruginosa: MIC >64 μg/ml is rarely achieved in vivo.
• Poor Gram-positive coverage: Laboratory concentrations required for inhibition exceed clinical relevance.
• Water/Ethanol insolubility: Stock solutions require DMSO and ultrasonic assistance at ≥12.65 mg/mL (APExBIO).
• Short half-life: Not suitable for sustained exposure models unless dosing is adjusted.
• Not for long-term solution storage: Instability in solution mandates fresh preparation for reproducibility.

This article expands on previous reviews by providing rigorous, up-to-date quantitative benchmarks, and clarifies Cinoxacin's mechanistic distinctions from newer quinolone derivatives.

Workflow Integration & Parameters

Cinoxacin is provided by APExBIO as SKU BA1045 (product page). For bench workflows:

• Solubility: Dissolve at ≥12.65 mg/mL in DMSO using ultrasonic bath; do not use water or ethanol as primary solvents.
• Assay range: Use 1–256 μg/ml for broth/agar dilution; 30 μg/disk for disk diffusion.
• Storage: Store solid at -20°C; avoid prolonged solution storage.
• Controls: Always include nalidixic acid and a Gram-positive control to verify assay specificity.
• Cross-reference: Compare effects with published workflows (Cinoxacin: Quinolone Antibiotic Workflows) for troubleshooting and advanced applications. This article provides more granular pharmacokinetic and MIC data than the referenced workflow guides.

Conclusion & Outlook

Cinoxacin remains a precise, well-characterized quinolone antibiotic for Gram-negative bacterial research and antibiotic resistance studies. Its defined solubility, dosing, and assay parameters make it indispensable for laboratory investigation of bacterial DNA replication inhibition. While surpassed clinically by newer fluoroquinolones, Cinoxacin's atomic benchmarks and reproducibility ensure ongoing relevance in translational and mechanistic microbiology. Researchers are advised to leverage APExBIO's standardized BA1045 product for high-fidelity results, and to integrate contemporary resistance and pharmacodynamic data for evolving experimental needs.